Vuity (Pilocarpine HCl) Patent Expiration, LOE Window & CMS Spending

Vuity (Pilocarpine HCl) by AbbVie: FDA Orange Book LOE 2039-04-24, 4 AB generics, $448K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAbbVie
FDA Application & PathwayN214028 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2039-04-24
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors4
2024 CMS Total Public Spend$448K
2024 Medicare Part D Spend$226K
2024 Medicaid Spend$221K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AbbVie across sibling Meru public-data platforms.